|
KMID : 1001020190170020096
|
|
Journal of Urologic Oncology
2019 Volume.17 No. 2 p.96 ~ p.102
|
|
|
Early Experiences with Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Failed Target Therapy
|
|
Lee Jong-Hoon
Kang Min-Yong
Chung Jae-Hoon
Sung Hyun-Hwan
Jeon Ha-Lim
Jeong Byung-Chang
Jeon Seong-Soo
Lee Hyun-Moo
Park Se-Hoon
Kim Binnari
Kwon Ghee-Young
Seo Seong-Il
|
|
|
Abstract
|
|
|
Purpose: The efficacy of nivolumab in metastatic renal cell carcinoma (mRCC) has been proven. However, the nivolumab experience in Korean patients with mRCC is still poorly reported. We report initial experiences with the efficacy and safety of nivolumab in patients with mRCC.
Materials and Methods: We retrospectively reviewed records for 25 patients with mRCC who had failed targeted therapy and were treated by nivolumab (2 mg/kg, every 2 weeks) at a single institution. The primary endpoint was objective response rate (ORR), and secondary endpoints were progression-free survival (PFS), safety profiles, and ORR in a programmed cell death receptor ligand 1 (PD-L1) expression subgroup.
Results: The median age was 60 years and 16 patients (64%) were male. Objective responses were achieved in 8 patients (32.0%) (complete response, 1; partial response, 7). Median PFS was 3.0 months (95% confidence interval, 1.46?4.53). Treatment-related adverse events (AEs) of any grade were observed in 19 patients (76.0%) with 6 (24.0%) experiencing grade 3 to 4 treatment-related AEs. In subgroups by PD-L1 expression levels classified as 1% or greater and less than 1%, ORR was 50% and 0%, respectively.
Conclusions: This study showed the efficacy and safety of initial experiences with nivolumab in Korean patients with mRCC who had failed targeted therapy. Our results were comparable to recent clinical trials on nivolumab in mRCC.
|
|
|
KEYWORD
|
|
|
Metastasis, Monoclonal antibody, Programmed cell death 1 ligand 1, Renal cell carcinoma, Treatment outcome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|